Home › Funds › FARALLON CAPITAL MANAGEMENT, L.L.C. › PTGX

FARALLON CAPITAL MANAGEMENT, L.L.C. position in PTGX

PROTAGONIST THERAPEUTICS INC · Health Care

FARALLON CAPITAL MANAGEMENT, L.L.C. reported holding 6,348,906 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$778.2M, representing 3.61% of its reported portfolio and ranking #5 among its reported holdings. FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed PTGX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)6.35M sh
Reported value held$778.25M
Portfolio Weight3.61%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How FARALLON CAPITAL MANAGEMENT, L.L.C.'s PTGX position evolved

FARALLON CAPITAL MANAGEMENT, L.L.C. first disclosed a stake in PTGX in Q3 2023 at 5,446,430 shares (US$90.8M). The position peaked in Q2 2026 at 6,348,906 shares, worth US$778.2M. Across 12 filings, FARALLON CAPITAL MANAGEMENT, L.L.C. increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 6,348,906 shares valued at US$778.2M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 5.45M $90.85M New
Q4 2023 5.73M $131.49M Add
Q1 2024 5.74M $166.03M Hold
Q2 2024 5.84M $202.38M Add
Q3 2024 5.86M $263.75M Hold
Q4 2024 5.93M $228.90M Add
Q1 2025 6.11M $295.33M Add
Q2 2025 6.17M $341.13M Add
Q3 2025 6.20M $411.60M Hold
Q4 2025 6.14M $536.62M Reduce
Q1 2026 6.35M $669.17M Add
Q2 2026 6.35M $778.25M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTGX and 13F data

PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), RTW INVESTMENTS, LP (US$620.4M), JOHNSON & JOHNSON (US$300.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTGX

All PTGX fund holders →

FAQ

How long has FARALLON CAPITAL MANAGEMENT, L.L.C. held PTGX?

FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed PTGX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is FARALLON CAPITAL MANAGEMENT, L.L.C.'s current position in PTGX?

As of Q2 2026, FARALLON CAPITAL MANAGEMENT, L.L.C. holds 6.35M shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $778.25M, representing 3.61% of its reported portfolio and ranking #5.

Has FARALLON CAPITAL MANAGEMENT, L.L.C. been buying or selling PTGX?

In the latest 13F filing (Q2 2026), FARALLON CAPITAL MANAGEMENT, L.L.C. held unchanged its position in PTGX. The position peaked in Q2 2026 at 6.35M shares.

Which other funds hold PTGX?

Other major institutional holders of PTGX include Farallon Capital Management, RTW INVESTMENTS, LP, JOHNSON & JOHNSON, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.